RADX (Radiopharm Theranostics) 5-Year EBITDA Growth Rate: 0.00% (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RADX Radiopharm Theranostics Ltd RADX
33 GF Score
Price $2.08
GF Value $2.34
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Radiopharm Theranostics 5-Year EBITDA Growth Rate?

Radiopharm Theranostics RADX -1.42% 33 5-Year EBITDA Growth Rate is 0.00% as of Jun. 2025. GuruFocus rates RADX with a GF Score™ of 33/100 and a GF Value™ of $2.34 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Radiopharm Theranostics's EBITDA per Share for the six months ended in Jun. 2025 was $-1.72.

During the past 3 years, the average EBITDA Per Share Growth Rate was 45.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Radiopharm Theranostics was 45.80% per year. The lowest was 41.50% per year. And the median was 43.65% per year.

Radiopharm Theranostics  (NAS:RADX) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Radiopharm Theranostics 5-Year EBITDA Growth Rate Related Terms

RADX vs VRTX, REGN, MRNA: 5-Year EBITDA Growth Rate Comparison

For the Biotechnology subindustry, Radiopharm Theranostics's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Radiopharm Theranostics 5-Year EBITDA Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Radiopharm Theranostics's 5-Year EBITDA Growth Rate falls into.


RADX
33GF Score
Radiopharm Theranostics Ltd RADX
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Radiopharm Theranostics 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 0.00% mean?
Radiopharm Theranostics (RADX) has a 5-Year EBITDA Growth Rate of 0.00% as of Jun. 2025. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Radiopharm Theranostics and its competitors.
Is Radiopharm Theranostics' 5-Year EBITDA Growth Rate too high?
Radiopharm Theranostics' current 5-Year EBITDA Growth Rate is 0.00%. Overall, Radiopharm Theranostics has a GF Score™ of 33/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Radiopharm Theranostics' 5-Year EBITDA Growth Rate compare to VRTX and REGN?
Radiopharm Theranostics' 5-Year EBITDA Growth Rate of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Biotechnology company?
A good 5-Year EBITDA Growth Rate depends on the Biotechnology industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Radiopharm Theranostics and its competitors. Radiopharm Theranostics's current 5-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radiopharm Theranostics stock overvalued right now?
Based on GuruFocus' analysis, Radiopharm Theranostics (RADX) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.34, compared to a current price of $2.08 — trading 11.1% below its estimated fair value. The current 5-Year EBITDA Growth Rate is 0.00%. Radiopharm Theranostics' overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Radiopharm Theranostics (RADX), the current 5-Year EBITDA Growth Rate is 0.00% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Radiopharm Theranostics (RADX) Overvalued in 2026?

Based on GuruFocus' analysis, Radiopharm Theranostics stock appears to be undervalued. The current stock price of $2.08 is trading 11.1% below its estimated GF Value™ of $2.34. GuruFocus considers Radiopharm Theranostics to be Modestly Undervalued.

Key valuation signals for RADX:

  • 5-Year EBITDA Growth Rate: 0.00%
  • GF Value™: $2.34 vs. price of $2.08 (11.1% below fair value)
  • GF Score™: 33/100 with 6 warning signs

No single metric tells the full story. See the RADX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Radiopharm Theranostics Business Description

Other Exchanges RAD:Australia
Address 62 Lygon Street, Suite 1, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
33GF Score

Get the complete analysis for RADX

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.08
Price
$2.34
GF Value